Sajan Joseph

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours

Anthony W. Tolcher, Jonathan H. Goldman, Amita Patnaik et al. · European Journal of Cancer · 2014 · 61 citations

Medicine, Oncology, Pharmacology +10

Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors

Rima Al‐awar, James E. Ray, Kyle A. Hecker et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 30 citations · Full text

Natural Sciences, Medicinal Chemistry, Pharmacology +13

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

Huaxing Pei, Saravanan Parthasarathy, Sajan Joseph et al. · Cancer Research · 2017 · 29 citations

Medicine, Oncology, Pharmacology +16

1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors

Rima Al‐awar, James E. Ray, Kyle A. Hecker et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 27 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11